Adicet Bio (ACET) Share-based Compensation (2017 - 2026)

Adicet Bio has reported Share-based Compensation for 10 years, with the latest figure at $1.7 million in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 90.68% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 90.68% decrease from a year earlier, with the FY2025 full-year figure at $14.3 million, down 35.68% from the prior year.
• Share-based Compensation was $1.7 million for Q2 2026 at Adicet Bio, up from $1.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $18.4 million in Q1 2025, with the low at $1.6 million in Q1 2026.
• Average Share-based Compensation over 5 years is $8.8 million, with a median of $7.0 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation jumped 93.75% in 2025, then slumped 91.38% in 2026.
• Over 5 years, Share-based Compensation stood at $4.2 million in 2022, then rose by 16.52% to $5.0 million in 2023, then plunged by 67.69% to $1.6 million in 2024, then surged by 93.75% to $3.1 million in 2025, then sank by 45.33% to $1.7 million in 2026.
• The last three Share-based Compensation figures came in at $1.7 million (Q2 2026), $1.6 million (Q1 2026), and $3.1 million (Q4 2025), per Business Quant data.